KR20240111800A - 인터루킨-23 수용체의 펩티드 억제제 - Google Patents

인터루킨-23 수용체의 펩티드 억제제 Download PDF

Info

Publication number
KR20240111800A
KR20240111800A KR1020247021622A KR20247021622A KR20240111800A KR 20240111800 A KR20240111800 A KR 20240111800A KR 1020247021622 A KR1020247021622 A KR 1020247021622A KR 20247021622 A KR20247021622 A KR 20247021622A KR 20240111800 A KR20240111800 A KR 20240111800A
Authority
KR
South Korea
Prior art keywords
glu
bridge
arg
ala
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247021622A
Other languages
English (en)
Korean (ko)
Inventor
헨리크 피셔 뭉크
닐스 비예르 홀름
라스무스 레스
비얀 듀 라르센
예스퍼 모솔프 마티젠
옥타브 칼다라루
Original Assignee
질랜드 파마 에이/에스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 질랜드 파마 에이/에스 filed Critical 질랜드 파마 에이/에스
Publication of KR20240111800A publication Critical patent/KR20240111800A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
KR1020247021622A 2021-12-01 2022-12-01 인터루킨-23 수용체의 펩티드 억제제 Pending KR20240111800A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21211815.2 2021-12-01
EP21211815 2021-12-01
PCT/EP2022/084077 WO2023099669A1 (en) 2021-12-01 2022-12-01 Peptide inhibitors of interleukin-23 receptor

Publications (1)

Publication Number Publication Date
KR20240111800A true KR20240111800A (ko) 2024-07-17

Family

ID=78821013

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247021622A Pending KR20240111800A (ko) 2021-12-01 2022-12-01 인터루킨-23 수용체의 펩티드 억제제

Country Status (12)

Country Link
US (1) US20250154198A1 (https=)
EP (1) EP4440592A1 (https=)
JP (1) JP2024543204A (https=)
KR (1) KR20240111800A (https=)
CN (1) CN118354781A (https=)
AU (1) AU2022402440A1 (https=)
CA (1) CA3240982A1 (https=)
CL (1) CL2024001598A1 (https=)
IL (1) IL313185A (https=)
MX (1) MX2024006556A (https=)
TW (1) TW202332682A (https=)
WO (1) WO2023099669A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4471048A1 (en) 2023-06-01 2024-12-04 Zealand Pharma A/S Peptide inhibitors of interleukin-23 receptor
EP4471049A1 (en) * 2023-06-01 2024-12-04 Zealand Pharma A/S Peptide inhibitors of interleukin-23 receptor
CN121794283A (zh) * 2023-09-08 2026-04-03 赛诺菲 作为选择性il-23受体抑制剂的新型肽
WO2026013260A1 (en) 2024-07-12 2026-01-15 Zealand Pharma A/S Peptide inhibitors of interleukin-23 receptor

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU723268B2 (en) 1996-09-09 2000-08-24 Zealand Pharma A/S Improved solid-phase peptide synthesis and agent for use in such synthesis
US8946150B2 (en) 2011-06-14 2015-02-03 Medical Diagnostic Laboratories, LLC. Polypeptides that bound to IL-23 receptor and inhibit binding of IL-23 and cell signaling thereof
CN107206254B (zh) 2014-07-17 2021-08-24 领导医疗有限公司 白细胞介素-23受体的口服肽抑制剂以及其治疗炎症性肠病的用途
MX384213B (es) 2015-07-15 2025-03-14 Protagonist Therapeutics Inc Inhibidores peptidicos del receptor de interleucina 23 y su uso para tratar enfermedades inflamatorias.
WO2018022937A1 (en) 2016-07-27 2018-02-01 Protagonist Therapeutics, Inc. Peptide inhibitors of interleukin-23 and their use to treat inflammatory diseases
WO2018089693A2 (en) 2016-11-09 2018-05-17 Protagonist Therapeutics, Inc. Methods for determining and monitoring gastrointestinal inflammation
WO2018136646A1 (en) 2017-01-18 2018-07-26 Protagonist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
WO2020014646A1 (en) 2018-07-12 2020-01-16 Protagonist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
WO2021007433A1 (en) 2019-07-10 2021-01-14 Protagonist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
AU2021209086A1 (en) * 2020-01-15 2022-08-04 Janssen Biotech, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
CA3167751A1 (en) 2020-01-15 2021-07-22 Janssen Biotech, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
WO2021146458A1 (en) 2020-01-15 2021-07-22 Protagonist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases

Also Published As

Publication number Publication date
CL2024001598A1 (es) 2024-11-15
IL313185A (en) 2024-07-01
MX2024006556A (es) 2024-06-12
TW202332682A (zh) 2023-08-16
WO2023099669A1 (en) 2023-06-08
CA3240982A1 (en) 2023-06-08
US20250154198A1 (en) 2025-05-15
AU2022402440A1 (en) 2024-05-30
CN118354781A (zh) 2024-07-16
JP2024543204A (ja) 2024-11-19
EP4440592A1 (en) 2024-10-09

Similar Documents

Publication Publication Date Title
KR20240111800A (ko) 인터루킨-23 수용체의 펩티드 억제제
JP7819087B2 (ja) インターロイキン－２３受容体のペプチド阻害剤および炎症性疾患を治療するためのそれらの使用
JP2023078369A (ja) γｃサイトカイン活性の安定な調節剤
JP2015510505A (ja) グレリン類似体
JP6143270B2 (ja) マイオスタチン阻害ペプチド
CA2793683A1 (en) Peptidomimetics for modulating interleukin-1 receptor
CN111788217A (zh) 白介素-15活性的拮抗剂肽
KR20250028290A (ko) 선택적 il-23 수용체 길항제로서의 새로운 펩티드
EP4471049A1 (en) Peptide inhibitors of interleukin-23 receptor
EP4471048A1 (en) Peptide inhibitors of interleukin-23 receptor
WO2014095977A1 (en) Novel pellino peptide
TW202607011A (zh) 介白素－２３受體之胜肽抑制劑
KR20250163313A (ko) Tnf-알파 결합제 및 이를 사용하는 방법
WO2026013260A1 (en) Peptide inhibitors of interleukin-23 receptor
WO2025079064A1 (en) Interleukin-17 peptidomimetic inhibitors
KR20250166123A (ko) 신경계 복구를 위한 단백질 티로신 포스파타제 웨지 도메인 펩티드 이량체
Anderson The synthesis of biologically interesting pseudopeptides

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000